Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29328397
Publication Date : //

Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance.


Breast cancer tissues and adjacent tissues were collected from 32 patients who were treated in The Third Hospital of Chengde City. Reverse transcription‑quantitative polymerase chain reaction results demonstrated that, compared with the adjacent tissues, interleukin (IL)‑23/IL‑23 receptor (R) gene expression levels were notably higher in breast cancer tissues. Furthermore, IL‑23 and IL‑23R expression levels were positively correlated with patients' tumor size, TNM stage and metastasis. Recombinant human (rh) IL‑23 (10 ng/ml) was used for the stimulation of the MCF‑7 cell line. Effects of rh IL‑23 (10 ng/ml) on cell proliferation was detected after MCF‑7 cells were incubated with rh IL‑23 for 48 h. Whether pre‑treatment with polyclonal antibody (PAb) IL‑23p19, a neutralizing antibody specific for IL‑23, may influence the effects of IL‑23 on cell behavior was also investigated. Cell proliferation assay and cell apoptosis assay were evaluated using MTT assay and flow cytometry assay, respectively. Results suggested that PAb IL‑23p19 reduced IL-23-induced cell proliferation whereas induced IL‑23 inhibited cell apoptosis. Western blot analysis was performed for the detection of molecules that may be responsible for the aforementioned changes. Results indicated that PAb IL‑23p19 treatment reduced IL‑23‑induced upregulation of B‑cell lymphoma‑2 protein expression and activation of the janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. The present results suggested that IL‑23 may be a potential prognosis marker and target for the treatment of breast cancer patients.

Authors : Sheng Shuhai , Zhang Jinji , Ai Jianzhong , Hao Xueli , Luan Ruishen ,

Related products :

Catalog number Product name Quantity
Breast - BRC481 Breast cancer array, 16 cases of breast cancer, each in duplicates, paired with corresponding uninvolved tissues from the same patients 2mm
1240 Breast cancer, matched metastatic carcinoma and cancer adjacent normal breast tissue array, including TNM, clinical stage and pathology grade, 48 cases_ 96 cores,
T081 Breast cancer test tissue array, with normal breast tissues as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T085
T081 Breast cancer test tissue array, with normal breast tissues as control, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by T085; ihc Anti-Actin confirmed
1106 Breast adjacent normal tissue array with breast cancer tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing BRN801
1185 Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing BR243i
1114 Breast cancer tissue array with adjacent normal breast tissue as control, including TNM, clinical stage and pathology grade, 110 cases_110 cores, replacing BC081116
BR243e Breast cancer tissue array with adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing BR243a; ihc Anti-Actin confirmed
BRN801a Breast adjacent normal tissue array with breast cancer tissue, including TNM, clinical stage and pathology grade, 80 cases_80 cores, replacing BRN801; ihc Anti-Actin confirmed
BR243f Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing BR243a; ihc Anti-Actin confirmed
BR243d Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replacing BR243c; ihc Anti-Actin confirmed
BR243c Breast cancer tissue array with matched adjacent normal breast tissue, including TNM, clinical stage and pathology grade, 6 cases_24 cores, replaced by BR243d; ihc Anti-Actin confirmed
1133 Breast cancer tissue array with cancer adjacent tissue as control, including TNM, clinical stage and pathology grade, 190 cases_ 192 cores, replacing BR1921
Breast - BRC1502 Breast cancer array, non_overlapping with BRC1501, consists of duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and other non_malignant breast tissues. 1.1mm
Breast - BRC961 Breast cancer array consists of duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal and other non_malignant breast tissues. 1.5mm
Breast - BRC1501 Breast cancer array consists of duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and other non_malignant breast tissues. 1.1mm
1113 Breast cancer tissue array with cancer adjacent normal tissue as control, including TNM, clinical stage and pathology grade, 72 cases_72 cores, replacing BC08013
Breast - BRC491 Breast cancer array, 49 cases of breast cancer, together with BRC711 forming the breast cancer array set. 1.7mm
Breast - BRC711 Breast cancer array, 71 cases of breast cancer, together with BRC491 forming the breast cancer array set. 1.1mm
1237 Breast cancer tissue array, including TNM, clinical stage and pathology grade, 49 cases_96 cores
1236 Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases_96 cores
27-424 Altered expression of GBX2, part of the homeobox-containing human family of DNA-binding transcription factors, is associated with therapy failure and death in patients with multiple types of cancer. 0.1 mg
1221 Breast cancer tissue array, including TNM, clinical stage and pathology grade, 40 cases_80 cores, replacing BR804
1132 Breast cancer tissue array, including TNM, clinical stage and pathology grade, 75 cases_150 cores, replacing BR1505
BR1003 Breast pre_cancerous disease and cancer tissue array (100 cases_101 cores), with clinical stage and pathology grade data


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur